Signals, Powered By EquityPandit
On Wednesday, Dr Reddy’s Laboratories has said that it has got three Form 483 observations from USFDA, for its Miryalaguda API plant in Telangana.
The nature of these observations has not been explained by the company.
The Miryalaguda plant had been one among the three plants for which the company got US drug regulator’s warning letter in November 2015.
The company has said that it is addressing the observations that has been raised by USFDA.
